KLOW Peptide Blend: What Is In It and What Each Component Is Studied For
KLOW is a supplied combination of four separate research peptides rather than a single molecule. Because it is a blend, evaluating it means evaluating each component independently — the literature on the mixture as a mixture is essentially non-existent, and any assessment has to be assembled from the individual compounds.
The four components
A KLOW blend combines BPC-157, TB-500 (a thymosin β4 fragment), GHK-Cu and KPV. They come from four unrelated peptide families and act through unrelated mechanisms, which is worth stating plainly: this is a co-formulation, not a designed multi-target molecule of the kind seen in incretin research.
BPC-157
A synthetic 15-amino-acid sequence derived from a fragment of human gastric juice protein BPC. The published work is overwhelmingly rodent, and much of it originates from a small number of research groups. Reported mechanisms in those models centre on nitric oxide signalling and on growth-factor receptor pathways. The indexed literature is available via PubMed.
TB-500
TB-500 is not thymosin β4 itself but a synthetic fragment corresponding to its actin-binding region. Thymosin β4 is a 43-residue G-actin sequestering protein, and the actin-binding motif is the part most studied in cell-migration assays. See the thymosin β4 literature.
GHK-Cu
A tripeptide (glycyl-L-histidyl-L-lysine) that forms a coordination complex with copper(II). The copper is not incidental — the peptide’s studied activity in fibroblast culture is tied to the complex rather than the free tripeptide. Literature: PubMed.
KPV
The C-terminal tripeptide of α-melanocyte-stimulating hormone (lysine-proline-valine). It has been examined in cell and rodent models of intestinal inflammation, generally as a melanocortin-pathway fragment that retains some activity without full receptor agonism. Literature: PubMed.
Why a blend complicates analysis
Four peptides in one vial creates two practical problems for a laboratory. The first is analytical: a purity figure for a blend is not a single number. Each component has its own retention time on RP-HPLC and its own mass, and a certificate has to resolve all four rather than reporting one aggregate peak. The second is experimental: any observed effect in a model system cannot be attributed to one component without running the components separately as controls.
For that reason, researchers designing component-level experiments generally source the individual peptides — BPC-157 and TB-500 and copper peptides are stocked separately — and reserve blends for work where the combination itself is the variable under study.
Net peptide content in a blend
An 80mg blend figure refers to total peptide across all four components, not 80mg of each. Anyone calculating concentrations for a specific component needs the per-component breakdown, and gross peptide weight is not the same as net peptide content once counter-ions and residual water are accounted for. That distinction is covered in more depth in our note on net peptide content.
Further reading
Each component above links to its indexed literature on PubMed. Certificates of analysis for the compounds we supply are published on this site; see how to read a certificate of analysis for guidance on interpreting them.
ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice, a dosing recommendation, or a suggestion of human or veterinary use. Certificates of analysis for each compound are published on this site.
